DOI:
10.1055/s-00000011
DMW - Deutsche Medizinische Wochenschrift
LinksClose Window
References
Tapson VF, Jing ZC, Xu KF et al.
Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
Chest 2013;
144: 952-8
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.